TY - JOUR TI - Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report A1 - Morganti, Alessio Giuseppe A2 - Macchia, Gabriella A3 - Frakulli, Rezarta A4 - Milanoi, Andrea A5 - Massari, Francesco A6 - Ntreta, Maria A7 - Siepe, Giambattista A8 - A9 - Arcelli, ra A10 - Cammelli, Silvia A11 - Rambaldi, Giuseppe Zanirato A12 - Fiorentino, Michelangelo A13 - Deodato, Francesco JF - European Journal of Medical Case Reports JO - EJMCR SN - 2520-4998 VL - 1 IS - 3 SP - 135 EP - 139 Y1 - 2017 AB - BackgroundCastration-resistant prostate cancer (CRPC) has a dismal prognosis. Despite treatment, median survival of these patients is around 12-22 months.Case Presentation In this report, we present the case of a 71-year-old man, with CRPC and painful bone metastases treated with an association of middle-half-body radiotherapy, androgen deprivation therapy (ADT) and cyclophosphamide-based metronomic chemotherapy. Five years after palliative radiotherapy the patient is still receiving metronomic chemotherapy and ADT. He is totally asymptomatic, with undetectable PSA values and negative 18F-Choline-PET/CT. The only side-effect was the development of non-insulin-dependent diabetes.ConclusionThis treatment for its tolerability and feasibility, it could be particularly useful in older patients with CRPC. Furthermore, considering the low costs, it could be an important therapeutic option for patients living in low-resourced countries. PB - https://www.ejmcr.com DO - 10.24911/ejmcr/1/32 UR - https://www.ejmcr.com/?mno=268832 ER -